PitchSend

Investor Presentaiton

Company overview Financial review 2022 priorities Appendix References KisqaliⓇ is the only CDK4/6i with consistent OS benefit seen across all three Ph3 trials KisqaliⓇ Ph3 OS results in 1L MBC KisqaliⓇ unique in inhibiting CDK4 8x more than CDK67-10 MONALEESA-2 Median OS Risk reduction 24% 63.9 months1 MONALEESA-7 Risk reduction 24% 58.6 months² MONALEESA-3 Risk reduction 33% 67.6 months3 Unbound Cavg relative to palbo 19x 16x 13x 10x 7x 4x Palbociclib 1x T Abemaciclib NATALEE adjuvant study on track NATALEE study design 3 INNOVATION RIB+ Ribociclib 400mg/day 3 weeks on/1 week off 36 months (-39 cycles) 36 months NSAI 60 months 60 months [+goserelin in pre-menopausal women & men] Ribociclib HR HER2-eBC Pre- and post- menopausal ET R 1:1 Anatomic Stage II & III 1x 2x 3x 4x 5x 6x 7x 8x CDK4:CDK6 inhibition from a cellular assay N=5000 NSAI 60 months 60 months [+goserelin in pre-menopausal women & men] " Longest median OS benefit ever published 4 ■ Same OS benefit regardless of menopausal status, hormone therapy partner, or dose modifications5 Maintains clinical benefit even after prior CDK4/6i use6 ■ At clinically relevant doses, KisqaliⓇ provides greater CDK4 inhibition in vivo than competitors Higher unbound Cavg means more drug available to act on tumor cells 7-10 Fully enrolled as of April 2021 Primary analysis planned at 500 iDFS events, expected in 2023 ■ Interim analyses at 70% and 85% See last slide for other references 1. In months vs. vs 51.4, P value: 0.008. Reference: Hortobagyi, GN et al., 2022 2. vs 51.8. Reference: Lu, YS et al., 2022 3. vs 51.4. Reference: Neven, P et al., 2022 4. for HR+/HER2- MBC 18 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation